Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
FLUPHENAZINE vs THIOTHIXENE HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with high potency and additional antagonism at alpha-adrenergic, muscarinic, and histaminergic receptors.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has affinity for serotonin 5-HT2, histamine H1, and alpha-1 adrenergic receptors, contributing to its therapeutic and adverse effects.
Fluphenazine decanoate (long-acting): 12.5-25 mg IM every 2 weeks; Fluphenazine hydrochloride (oral): 2.5-10 mg daily in divided doses; initial titration 2.5-10 mg/day, maintenance 1-5 mg/day. Maximum oral dose 20 mg/day.
Initial: 2 mg orally three times daily. Maintenance: 15-30 mg orally daily in divided doses. Maximum: 60 mg/day.
None Documented
None Documented
Clinical Note
moderateFluphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone propionate."
Clinical Note
moderateFluphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Fluphenazine."
Clinical Note
moderateFluphenazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life is 15-30 hours, but may extend to 40-50 hours after chronic use; clinical context: dosing interval is typically 12-24 hours, and steady-state is reached within 3-5 days.
Terminal elimination half-life ranges from 26 to 36 hours in healthy adults, allowing for once-daily dosing in maintenance therapy. In chronic use, the half-life may be prolonged due to accumulation.
Primarily hepatic metabolism with biliary excretion. Less than 1% excreted unchanged in urine; fecal elimination accounts for approximately 20-30% of metabolites.
Primarily renal and biliary; about 50-60% of a single dose is excreted in the urine as metabolites and unchanged drug within 48 hours, with approximately 30-40% eliminated in feces via biliary secretion. Less than 1% of the parent drug is excreted unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
Fluphenazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine."